Lexeo Therapeutics (LXEO) Capital Leases (2022 - 2026)

Lexeo Therapeutics' Capital Leases history runs 5 years deep, the most recent figure standing at $198000.0 for Q1 2026.

• In Q1 2026, Capital Leases fell 71.63% year-over-year to $198000.0; the TTM figure through Mar 2026 stood at $198000.0 (down 71.63% YoY), while the FY2025 annual figure was $327000.0, down 59.98% from the prior year.
• Capital Leases came in at $198000.0 for Q1 2026 at Lexeo Therapeutics, down from $327000.0 in the prior quarter.
• In the past five years, Capital Leases ranged from a high of $1.6 million in Q4 2022 to a low of $198000.0 in Q1 2026.
• A 5-year average of $870333.3 and a median of $873500.0 in 2024 frame the typical range for Capital Leases.
• Across the five-year window, Capital Leases decreased 24.33% in 2023 and sank 71.63% in 2026, its largest moves.
• Lexeo Therapeutics' Capital Leases stood at $1.6 million in 2022, then slipped by 24.33% to $1.2 million in 2023, then tumbled by 34.48% to $817000.0 in 2024, then tumbled by 59.98% to $327000.0 in 2025, then sank by 39.45% to $198000.0 in 2026.
• According to Business Quant data, Capital Leases over the past three periods registered $198000.0, $327000.0, and $454000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison